TY - JOUR
T1 - Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis
AU - Weier, Katrin
AU - Penner, Iris K.
AU - Magon, Stefano
AU - Amann, Michael
AU - Naegelin, Yvonne
AU - Andelova, Michaela
AU - Derfuss, Tobias
AU - Stippich, Christoph
AU - Radue, Ernst Wilhelm
AU - Kappos, Ludwig
AU - Sprenger, Till
N1 - Funding Information:
I.K. Penner has received research grants from Bayer AG Switzerland; has received honoraria for serving as speaker at scientific meetings, as a consultant, and as a member of scientific advisory boards for Actelion, Bayer Pharma AG, Biogen Idec, Merck Serono, Roche, and Teva Aventis. M. Amann received travel support from Novartis. M. Andelova received travel support from Novartis. T. Derfuss served on advisory boards for Novartis, Merck-Serono, Bayer Schering, Biogen Idec, Genzyme and TEVA. He received travel support from Biogen Idec, Bayer Schering, Genzyme and Merck Serono. He received research and/or unrestricted grants from Novartis, Biogen Idec, Merck Serono. The Department of Radiology, University Hospitals Basel, Switzerland receives financial support from Bayer Healthcare, Bracco and Guerbet and has a research agreement with SIEMENS Medical Solutions. The submitted work is not related to these agreements. C. Stippich receives no other financial support related to the submitted work. E.W. Radue received honoraria for serving as speaker at scientific meetings and consultant for Novartis, Biogen Idec, Merck Serono, Bayer Schering. He received financial support for research activities from Actelion, Basilea Pharmaceutica Ltd, Biogen Idec, Merck Serono and Novartis. L. Kappos received institutional research support from Acorda, Actelion, Allozyne, BaroFold, Bayer HealthCare, Bayer Schering, Bayhill, Biogen Idec, Boehringer Ingelheim, Elan, Genmab, Glenmark, GlaxoSmithKline, Merck Serono, MediciNova, Novartis, sanofi-aventis, Santhera, Shire, Roche, Teva, UCB, Wyeth. T. Sprenger served on advisory boards for Mitsubishi Pharma, Genzyme, Eli Lilly, Biogen Idec, ATI and Allergan. He received travel support from Pfizer, Bayer Schering, Eli Lilly and Allergan. All remaining authors have nothing to disclose. T. Derfuss is a PLOS ONE Editorial Board member. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
PY - 2014/1/22
Y1 - 2014/1/22
N2 - The cerebellum is known to be involved not only in motor but also cognitive and affective processes. Structural changes in the cerebellum in relation to cognitive dysfunction are an emerging topic in the field of neuro-psychiatric disorders. In Multiple Sclerosis (MS) cerebellar motor and cognitive dysfunction occur in parallel, early in the onset of the disease, and the cerebellum is one of the predilection sites of atrophy. This study is aimed at determining the relationship between cerebellar volumes, clinical cerebellar signs, cognitive functioning and fatigue in MS. Cerebellar volumetry was conducted using T1-weighted MPRAGE magnetic resonance imaging of 172 MS patients. All patients underwent a clinical and brief neuropsychological assessment (information processing speed, working memory), including fatigue testing. Patients with and without cerebellar signs differed significantly regarding normalized cerebellar total volume (nTCV), normalized brain volume (nBV) and whole brain T2 lesion volume (LV). Patients with cerebellar dysfunction likewise performed worse in cognitive tests. A regression analysis indicated that age and nTCV explained 26.3% of the variance in SDMT (symbol digit modalities test) performance. However, only age, T2 LV and nBV remained predictors in the full model (r 2 = 0.36). The full model for the prediction of PASAT (Paced Auditory Serial Addition Test) scores (r2 = 0.23) included age, cerebellar and T2 LV. In the case of fatigue, only age and nBV (r2 = 0.17) emerged as significant predictors. These data support the view that cerebellar abnormalities contribute to disability, including cognitive impairment in MS. However, this contribution does not seem to be independent of, and may even be dominated by wider spread MS pathology as reflected by nBV and T2 LV.
AB - The cerebellum is known to be involved not only in motor but also cognitive and affective processes. Structural changes in the cerebellum in relation to cognitive dysfunction are an emerging topic in the field of neuro-psychiatric disorders. In Multiple Sclerosis (MS) cerebellar motor and cognitive dysfunction occur in parallel, early in the onset of the disease, and the cerebellum is one of the predilection sites of atrophy. This study is aimed at determining the relationship between cerebellar volumes, clinical cerebellar signs, cognitive functioning and fatigue in MS. Cerebellar volumetry was conducted using T1-weighted MPRAGE magnetic resonance imaging of 172 MS patients. All patients underwent a clinical and brief neuropsychological assessment (information processing speed, working memory), including fatigue testing. Patients with and without cerebellar signs differed significantly regarding normalized cerebellar total volume (nTCV), normalized brain volume (nBV) and whole brain T2 lesion volume (LV). Patients with cerebellar dysfunction likewise performed worse in cognitive tests. A regression analysis indicated that age and nTCV explained 26.3% of the variance in SDMT (symbol digit modalities test) performance. However, only age, T2 LV and nBV remained predictors in the full model (r 2 = 0.36). The full model for the prediction of PASAT (Paced Auditory Serial Addition Test) scores (r2 = 0.23) included age, cerebellar and T2 LV. In the case of fatigue, only age and nBV (r2 = 0.17) emerged as significant predictors. These data support the view that cerebellar abnormalities contribute to disability, including cognitive impairment in MS. However, this contribution does not seem to be independent of, and may even be dominated by wider spread MS pathology as reflected by nBV and T2 LV.
UR - http://www.scopus.com/inward/record.url?scp=84899522278&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0086916
DO - 10.1371/journal.pone.0086916
M3 - Article
C2 - 24466290
AN - SCOPUS:84899522278
SN - 1932-6203
VL - 9
JO - PLoS ONE
JF - PLoS ONE
IS - 1
M1 - e86916
ER -